Cochlear’s share price slump reflects profit downgrades, slowing growth, weak global demand, and macro pressures. The stock is down sharply, but a lasting bottom likely depends on stabilising earnings and clearer signs of demand recovery.
SportsHero (ASX: SHO) is up over 300%, driven by deals and funding, but is now consolidating after a sharp rally, with further upside dependent on holding support.
PlaySide Studios is shifting from contract development to original IP and publishing to boost margins and growth. Strong partnerships and a solid pipeline support optimism, but revenue volatility and past unprofitability keep investor sentiment cautious.
Investing in the Australian stock market offers stability, strong regulation, and exposure to globally essential industries like mining and finance. With diverse sectors and proximity to Asia’s growth, the ASX provides long-term opportunities in a mature, reliable market.
Botanix Pharmaceuticals has seen a sharp volume spike after a major share price decline, hinting at possible bottoming. While Sofdra sales are growing and funding has improved liquidity, the stock remains in a downtrend, with any recovery dependent on stronger fundamentals and a break above key resistance.
Qantas (ASX: QAN) has pulled back sharply in 2026, but the decline is largely driven by cyclical pressures rather than a broken business. The key trigger has been a surge in jet fuel costs, which have more than doubled in recent months.
